PE Tech Report


Like this article?

Sign up to our free newsletter

Odyssey’s ProPharma Group acquires Diamond Pharma Services

ProPharma Group, a portfolio company of Odyssey Investment Partners, has acquired Diamond Pharma Services.  

Diamond Pharma Services provides regulatory affairs, pharmacovigilance, and compliance & quality services to support pharmaceutical and biotechnology companies in obtaining and maintaining medicinal product licenses throughout all stages of a product’s life cycle.
“We are excited to welcome Diamond Pharma Services into the ProPharma Group family,” says Dawn Sherman, ProPharma Group’s CEO. “This acquisition further solidifies ProPharma Group’s position as the leading global provider of regulatory, compliance, pharmacovigilance, and medical information services. With our mission and higher purpose of improving the health and safety of patients, we are focused on delivering the highest quality of services throughout the full product lifecycle.”
With global presence and headquarters based in Harlow, United Kingdom, Diamond Pharma Services brings a suite of regulatory, pharmacovigilance, and compliance and quality capabilities that is perfectly aligned with ProPharma Group’s core services. As an award-winning team of regulatory experts with deep subject matter knowledge for handling challenging therapeutic classes, Diamond’s team will help accelerate the value ProPharma Group brings in delivering regulatory science to companies working on cutting-edge therapeutics with ProPharma Group’s ATMPs/Cell and Gene Therapy Center of Excellence. Diamond’s Pharmacovigilance services also bolster ProPharma Group’s global reach and capabilities through additional capacity and expertise with a wide range of products from generics to advanced therapies. 
“Joining forces with ProPharma Group offers a fantastic opportunity to enhance the ways in which our teams can bring value to our customers, working together to improve the health and safety of patients. Our complementary experience and expertise will allow us to bring even more depth and breadth to the services we provide our clients,” says Maureen Graham, Founder, Diamond Pharma Services.
ProPharma Group continues to expand its global presence with more than 1,300 employees across North America, Europe, Japan, and Australia. As a trusted partner to its clients, ProPharma Group delivers excellence in everything we do by bringing together the best talent around the world to tackle complex challenges.
Jeff McKibben, Senior Managing Principal of Odyssey Investment Partners, says: “Odyssey supports the ProPharma Group team in the quest to deliver a differentiated portfolio of services with the mission to improve the health and safety of patients around the world. We are confident the addition of Diamond Pharma Services will accelerate ProPharma Group’s growth and enhance its reputation as a value-added partner to its clients.”
Achelous Partners served as M&A advisor to Diamond Pharma Services on the transaction.

Like this article? Sign up to our free newsletter